An interventional study of Caffeine and L-Citrulline in Exercise Physiology and Nutritional Supplementation, sponsored by St. Louis University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by St. Louis University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will examine how three commonly used pre-run nutritional supplements-caffeine, L-citrulline, and an exogenous ketone supplement-affect physiological and perceptual responses during a fixed-pace 5 km treadmill run in healthy, physically active runners.
Participants will complete one screening and baseline visit followed by four experimental visits in a randomized order. At each experimental visit, participants will receive caffeine, L-citrulline, an exogenous ketone supplement, or placebo before completing a fixed-pace 5 km treadmill run. Each participant will receive all four conditions and will therefore serve as their own control.
The study will evaluate measures including running economy, heart-rate responses, oxygen consumption, respiratory measures, blood lactate and ketone concentrations, perceived exertion, gastrointestinal symptoms, fatigue, energy, and focus. A randomly selected subgroup will also wear a continuous glucose monitor to explore glucose responses during the experimental visits. The study will also assess the feasibility and tolerability of completing repeated treadmill trials under the four supplement conditions.
This is a randomized, single-blind, placebo-controlled crossover study designed to compare acute physiological and perceptual responses to three pre-run nutritional supplements and placebo during a controlled fixed-pace 5 km treadmill run. Healthy, physically active runners will complete one screening/baseline visit and four experimental visits. Each participant will complete all four experimental conditions in randomized order and will serve as their own control. A minimum washout/recovery period of four days will separate experimental visits.
At each experimental visit, participants will receive one of four pre-run conditions: caffeine at 4 mg/kg body weight, L-citrulline at 7 g, an exogenous ketone supplement providing 11.5 g beta-hydroxybutyrate (BHB), or placebo. Study products will be provided in a standardized beverage vehicle, followed by a 45-minute waiting period before the treadmill run.
The primary physiological outcomes of interest are running economy and heart-rate drift during the fixed-pace 5 km treadmill run. Additional outcomes include oxygen consumption, carbon dioxide production, ventilation, respiratory exchange ratio, heart-rate recovery, capillary blood lactate and ketone concentrations, rating of perceived exertion, gastrointestinal symptoms, subjective fatigue, energy, focus, and participant-reported perceptions of the assigned supplement condition.
A prespecified randomly selected subgroup of up to 12 enrolled participants will use a Dexcom Stelo continuous glucose monitor during the experimental phase. CGM-derived glucose responses will be analyzed as exploratory outcomes within this subgroup only.
The study will also evaluate feasibility and tolerability, including visit completion, adverse events, supplement-related symptoms, gastrointestinal symptoms, and completeness of study measurements. The results are intended to characterize within-participant differences among the four conditions and provide preliminary data for future confirmatory studies.
St. Louis University is the lead sponsor of 156 studies on the registry; 17 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this randomized crossover sequence will receive caffeine, followed by L-citrulline, placebo, and exogenous ketone across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.
Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage
Participants assigned to this randomized crossover sequence will receive L-citrulline, followed by exogenous ketone, caffeine, and placebo across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.
Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage
Participants assigned to this randomized crossover sequence will receive exogenous ketone, followed by placebo, L-citrulline, and caffeine across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.
Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage
Participants assigned to this randomized crossover sequence will receive placebo, followed by caffeine, exogenous ketone, and L-citrulline across four experimental visits. Each intervention will be administered 45 minutes before a fixed-pace 5 km treadmill run. Experimental visits will be separated by a minimum washout/recovery period of four days.
Dietary Supplement: Caffeine · Dietary Supplement: L-Citrulline · Dietary Supplement: Exogenous Ketone (Beta-Hydroxybutyrate) · Other: placebo beverage
Caffeine will be administered at exactly 4 mg/kg body weight. The individualized dose will be calculated using body weight measured at the baseline visit. The commercially manufactured capsule contents will be weighed by trained study staff using a calibrated analytical balance to obtain the protocol-specified dose. Caffeine will be dispensed in the standardized study beverage and consumed 45 minutes before the fixed-pace 5 km treadmill run.
L-citrulline will be administered at exactly 7.0 g. The commercially manufactured pure L-citrulline powder will be weighed using a calibrated analytical balance, dispensed in the standardized study beverage, and consumed 45 minutes before the fixed-pace 5 km treadmill run.
The exogenous ketone condition will consist of one 15 g serving of Nutricost Ketone BHB Salt 4-in-1 Powder, providing 11.5 g beta-hydroxybutyrate (BHB) as calcium, magnesium, sodium, and potassium BHB salts. The supplement will be dispensed in the standardized study beverage and consumed 45 minutes before the fixed-pace 5 km treadmill run.
The placebo will be a study-prepared beverage containing water, food-grade lime flavoring, and stevia, with no active study supplement. It will use the same standardized final volume as the active conditions and will be consumed 45 minutes before the fixed-pace 5 km treadmill run.
Running Economy (VO₂) During the Fixed-Pace 5 km Treadmill Run
Running economy will be assessed using oxygen consumption (VO₂) measured by indirect calorimetry during standardized portions of the fixed-pace 5 km treadmill run. Within-participant running-economy responses will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits, approximately 45 minutes after supplement/placebo ingestion.
Heart-Rate Drift During the Fixed-Pace 5 km Treadmill Run
Heart-rate drift will be assessed from continuous heart-rate monitoring as the change in heart rate over the course of the fixed-pace 5 km treadmill run. Within-participant heart-rate drift will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: Throughout the fixed-pace 5 km treadmill run at each of the four experimental visits, approximately 45 minutes after supplement/placebo ingestion.
Mean Oxygen Consumption (VO₂) During the Fixed-Pace 5 km Treadmill Run
Oxygen consumption (VO₂) will be measured continuously by indirect calorimetry and summarized as the mean body-mass-normalized VO₂ (mL/kg/min) during the fixed-pace 5 km treadmill run. Within-participant mean VO₂ will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits, beginning approximately 45 minutes after supplement/placebo ingestion.
Mean Carbon Dioxide Production (VCO₂) During the Fixed-Pace 5 km Treadmill Run
Carbon dioxide production (VCO₂) will be measured continuously by indirect calorimetry and summarized as the mean VCO₂ (L/min) during the fixed-pace 5 km treadmill run. Within-participant mean VCO₂ will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits, beginning approximately 45 minutes after supplement/placebo ingestion.
Ventilation
Pulmonary ventilation will be measured using indirect calorimetry during the fixed-pace 5 km treadmill run and compared across supplement conditions.
Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits.
Respiratory Exchange Ratio
Respiratory exchange ratio (RER), calculated from oxygen consumption and carbon dioxide production, will be evaluated during the fixed-pace 5 km treadmill run and compared across supplement conditions.
Time frame: During the fixed-pace 5 km treadmill run at each of the four experimental visits.
1-Minute Heart-Rate Recovery After the Fixed-Pace 5 km Treadmill Run
Heart-rate recovery will be calculated as the decrease in heart rate from the end of the fixed-pace 5 km treadmill run to 60 seconds after exercise cessation, expressed in beats per minute. Within-participant 1-minute heart-rate recovery will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: From exercise cessation to 60 seconds after completion of the fixed-pace 5 km treadmill run at each of the four experimental visits.
Capillary Blood Lactate Concentration
Capillary blood lactate concentration will be measured using finger-prick blood sampling and a point-of-care analyzer before and after exercise. Pre- to post-exercise responses will be compared across supplement conditions.
Time frame: Immediately before and immediately after the fixed-pace 5 km treadmill run at each experimental visit.
Capillary Blood Ketone Concentration
Capillary blood ketone concentration will be measured using finger-prick blood sampling and a point-of-care analyzer before and after exercise. Pre- to post-exercise responses will be compared across supplement conditions.
Time frame: Immediately before and immediately after the fixed-pace 5 km treadmill run at each experimental visit.
Rating of Perceived Exertion
Rating of perceived exertion will be assessed using the Borg 6-20 Rating of Perceived Exertion scale, where 6 represents no exertion and 20 represents maximal exertion; higher scores indicate greater perceived exertion.
Time frame: During and immediately following the fixed-pace 5 km treadmill run at each experimental visit.
Gastrointestinal Symptoms Severity
Gastrointestinal symptoms, including nausea, urge to vomit, bloating, belching, and abdominal cramping, will be assessed using visual analog scales anchored from no symptoms to the worst imaginable severity for each symptom. Higher values indicate greater symptom severity. Responses will be compared across the four supplement conditions.
Time frame: During and immediately following the fixed-pace 5 km treadmill run at each experimental visit.
Subjective Fatigue
Participant-reported fatigue will be assessed using a single-item 0-10 numeric rating scale, where 0 indicates no fatigue and 10 indicates extreme fatigue. Scores and within-visit changes will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: Immediately before supplement/placebo ingestion and immediately following the fixed-pace 5 km treadmill run at each experimental visit.
Subjective Energy Level
Participant-reported energy will be assessed using a single-item 0-10 numeric rating scale, where 0 indicates no energy at all and 10 indicates extremely high energy. Scores and within-visit changes will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: Immediately before supplement/placebo ingestion and immediately following the fixed-pace 5 km treadmill run at each experimental visit.
Subjective Mental Focus
Participant-reported mental focus will be assessed using a single-item 0-10 numeric rating scale, where 0 indicates not at all focused and 10 indicates extremely focused. Scores and within-visit changes will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: Immediately before supplement/placebo ingestion and immediately following the fixed-pace 5 km treadmill run at each experimental visit.
Participant-Reported Guess of Assigned Supplement Condition
Following each experimental visit, participants will report which supplement condition they believe they received. Responses will be summarized and compared with the actual assigned condition to evaluate participant perception of treatment assignment.
Time frame: Immediately following completion of each experimental visit.
Interstitial Glucose Response During the Experimental-Visit Window in the CGM Subgroup
Interstitial glucose will be measured continuously using continuous glucose monitoring in the prespecified randomly selected CGM subgroup. Only CGM data collected from the pre-supplement baseline through completion of the immediate post-exercise assessments at each experimental visit will be retained for analysis. Inter-visit CGM data will not be analyzed. Within-participant glucose responses will be compared across the caffeine, L-citrulline, exogenous ketone, and placebo conditions.
Time frame: From pre-supplement baseline through completion of the immediate post-exercise assessments at each experimental visit.
Completion of All Four Experimental Visits
Feasibility will be assessed by the number and proportion of enrolled participants who complete all four randomized experimental visits and the full four-condition crossover protocol.
Time frame: Across each participant's approximately 4-6 weeks of study participation.
Participants Experiencing Adverse Events
Adverse events and adverse responses occurring in association with study supplementation or exercise testing will be recorded throughout study participation. The number and proportion of participants experiencing one or more adverse events will be summarized.
Time frame: From the first study visit through completion of the final study visit, approximately 4-6 weeks per participant.
Plan to share: No — Individual participant data will not be shared with outside researchers. Only de-identified, aggregate study results may be used for analysis, publication, or presentation, in accordance with the approved protocol and participant privacy protections.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Caffeine · Citrulline · 3-Hydroxybutyric Acid